OncoMatch/Non-Hodgkin Lymphoma (NHL)/PD-L1 (CD274)
Non-Hodgkin Lymphoma (NHL)PD-L1 (CD274) Clinical Trials
PD-L1 expression is an eligibility or stratification biomarker across multiple NHL subtypes: primary mediastinal B-cell lymphoma (PMBCL) shows high PD-L1/PD-L2 expression due to 9p24.1 amplification and responds well to pembrolizumab. Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and other NHL subtypes have ongoing PD-1 inhibitor trials. Trials explore checkpoint immunotherapy in PD-L1-enriched NHL subtypes, combinations with BTK or BCL2 inhibitors, and bispecific antibody plus IO regimens.
Top recruiting PD-L1 (CD274) Non-Hodgkin Lymphoma (NHL) trials
Ranked by phase and US site count. See all 3 trials matched to your profile →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
L & L Bio Co., Ltd., Ningbo, China
Browse other molecular targets with active Non-Hodgkin Lymphoma (NHL) trials.